Table 1.
Characteristics of patients not taking warfarin
| HCC n = 91 | LC n = 127 | P‐value | |
|---|---|---|---|
| Age (years) | 72 (36–87) | 64 (28–89) | <0.010 |
| Sex (male/female) | 73/18 | 78/56 | <0.010 |
| Etiology (HBV/HCV/alcohol/other) | 13/55/10/13 | 14/48/33/32 | <0.010 |
| Total bilirubin (mg/dL) | 0.7 (0.2–2.9) | 0.9 (0.2–8.6) | <0.010 |
| Albumin (g/dL) | 3.9 (2.6–5.0) | 3.8 (1.7–5.0) | 0.092 |
| ALT (IU/dL) | 32 (7–208) | 24 (5–129) | 0.047 |
| Platelet (×104) | 12.5 (2.7–32.5) | 9.0 (1.2–31.6) | <0.010 |
| PT‐INR | 1.03 (0.86–1.47) | 1.13 (0.9–2.1) | <0.010 |
| DCP (mAU/mL) | 52 (10–415 000) | 25 (7–1153) | <0.010 |
| NX‐PVKA ratio | 1.19 (0.52–48.2) | 0.95 (0.25–6.68) | <0.010 |
| AFP (ng/mL) | 10 (1–167 466) | 4 (1–138) | <0.010 |
| AFP L3 (%) | 0.5 (0–80.2) | 0 (0–13.6) | <0.010 |
| ucOC (ng/mL) | 1.88 (0.38–10.8) | 3.23 (0.38–19.80) | 0.224 |
| Child–Pugh (A/B/C) | 79/12 | ||
| UICC Stage (I/II/III/IV) | 39/41/7/4 | ||
| Size of tumor (mm) | 22 (6–150) | ||
| Number of tumors | 2 (1–20) | ||
| Primary/Recurrence | 52/39 | ||
| VP (+/−) | 13/78 |
AFP, α‐fetoprotein; ALT, alanine aminotransferase; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LC, liver cirrhosis; PT‐INR, prothrombin time‐international normalized ratio; UICC, Union for International Cancer Control; VP, portal vein invasion.